560 related articles for article (PubMed ID: 28625506)
1. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
Hunt B; Vega-Hernandez G; Valentine WJ; Kragh N
Diabetes Obes Metab; 2017 Jun; 19(6):842-849. PubMed ID: 28124820
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.
Hunt B; McConnachie CC; Gamble C; Dang-Tan T
J Med Econ; 2017 Nov; 20(11):1117-1120. PubMed ID: 28651479
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.
Mezquita-Raya P; Ramírez de Arellano A; Kragh N; Vega-Hernandez G; Pöhlmann J; Valentine WJ; Hunt B
Diabetes Ther; 2017 Apr; 8(2):401-415. PubMed ID: 28224463
[TBL] [Abstract][Full Text] [Related]
5. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.
Huetson P; Palmer JL; Levorsen A; Fournier M; Germe M; McLeod E
J Med Econ; 2015; 18(8):573-85. PubMed ID: 25853868
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
Hunt B; Mocarski M; Valentine WJ; Langer J
J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Yuan S; Wu Y
Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
11. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
Lee WC; Conner C; Hammer M
Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.
Roussel R; Martinez L; Vandebrouck T; Douik H; Emiel P; Guery M; Hunt B; Valentine WJ
J Med Econ; 2016; 19(2):121-34. PubMed ID: 26413789
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Gao L; Zhao FL; Li SC
Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.
Zhang X; Liu S; Li Y; Wang Y; Tian M; Liu G
PLoS One; 2016; 11(6):e0156393. PubMed ID: 27304904
[TBL] [Abstract][Full Text] [Related]
16. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m
Dilla T; Alexiou D; Chatzitheofilou I; Ayyub R; Lowin J; Norrbacka K
J Med Econ; 2017 May; 20(5):443-452. PubMed ID: 28008768
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
Raya PM; Blasco FJA; Hunt B; Martin V; Thorsted BL; Basse A; Price H
Diabetes Obes Metab; 2019 Jun; 21(6):1349-1356. PubMed ID: 30740861
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
Tzanetakos C; Melidonis A; Verras C; Kourlaba G; Maniadakis N
BMC Health Serv Res; 2014 Sep; 14():419. PubMed ID: 25245666
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.
Hunt B; Ye Q; Valentine WJ; Ashley D
Diabetes Ther; 2017 Feb; 8(1):129-147. PubMed ID: 28058656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
